摘要
目的通过检测血浆外泌体lncNORAD在膀胱癌(BCa)患者中的表达水平并分析与临床病理特征的相关性, 评价其作为肿瘤标志物对BCa的诊断效能。方法回顾性研究。采用简单随机抽样法选取同济大学附属同济医院于2021年10月1日至2023年10月 1日确诊的100例BCa患者作为患者组, 其中男76例, 女24例, 年龄(71±10)岁。同时期纳入40例泌尿系统良性病变者作为良性疾病组, 其中男33例, 女7例, 年龄(64±9)岁。以及70名健康体检者作为对照组, 其中包括男53名, 女17名, 年龄(45±12)岁。采用血浆外泌体提取试剂盒提取外泌体, 应用透射电镜、纳米颗粒跟踪分析和蛋白免疫印迹对外泌体进行形态学观察和分子表型鉴定;提取血浆外泌体中的总RNA, 实时荧光定量聚合酶链反应检测血浆外泌体lncNORAD的表达水平。在BCa患者组中以lncNORAD的相对表达水平的中位数作为截断值, 将BCa患者分为高表达组与低表达组, 并用χ^(2)检验比较其与临床病理特征的关系, 受试者工作特征(ROC)曲线判断其对BCa患者的诊断效能。结果患者组血浆外泌体lncNORAD的表达水平高于对照组(P<0.001)和炎性对照组(P<0.001), 且其高表达与TNM 分期(P=0.001, χ^(2)=10.187)、淋巴结转移(P=0.003, χ^(2)=8.575)、肿瘤分级(P=0.006, χ^(2)=7.440)和核基质蛋白22(NMP22, χ^(2)=5.844)(P=0.016)密切相关;ROC分析表明, 血浆外泌体lncNORAD诊断BCa的曲线下面积(AUC)为0.828(95%CI 0.772~0.883), 当外泌体lncNORAD与临床上常规标志物核基质蛋白22(NMP22)联合检测时诊断效能进一步提高(AUC=0.866, 95%CI 0.815~0.916)。结论 BCa患者血浆外泌体中 lncNORAD的表达上调与多个临床病理特征相关, 具有成为BCa诊断标志物的潜力。
Objective:To evaluate the diagnostic efficacy of plasma exosomal lncNORAD as a tumor marker for bladder cancer(BCa)by examining its expression levels in BCa patients and analyzing the correlation with clinical pathological characteristics.Methods:This retrospective study.100 BCa patients diagnosed between October 1,2021,and October 1,2023,at Tongji Hospital,Tongji University were randomly selected as the patient group(76 males,24 females,mean age 71±10 years).In the same period,40 patients with benign urinary system diseases(benign disease group;33 males,7 females,mean age 64±9 years)and 70 healthy individuals undergoing routine check-ups(control group;53 males,17 females,mean age 45±12 years)were included.Plasma exosomes were extracted using an exosome extraction kit,and morphologically and molecularly were characterized by transmission electron microscopy,nanoparticle tracking analysis,and Western blotting.Total RNA from plasma exosomes was extracted,and the expression level of exosomal lncNORAD was detected by real-time quantitative polymerase chain reaction.In the BCa patient group,patients were divided into high expression and low expression groups based on the median relative expression level of lncNORAD.Theχ^(2) test was used to compare the relationship between lncNORAD expression and clinical pathological characteristics,and the receiver operating characteristic(ROC)curve was used to evaluate its diagnostic efficacy for BCa.Results:The expression level of plasma exosomal lncNORAD in the patient group was significantly higher than that in the control group(P<0.001)and the benign disease group(P<0.001).High expression of lncNORAD was closely related to TNM stage(P=0.001,χ^(2)=10.187),lymph node metastasis(P=0.003,χ^(2)=8.575),tumor grade(P=0.006,χ^(2)=7.440),and nuclear matrix protein 22(NMP22,χ^(2)=5.844)(P=0.016).ROC analysis showed that the area under the curve(AUC)for diagnosing BCa with plasma exosomal lncNORAD was 0.828(95%CI 0.772-0.883).The diagnostic efficacy was further improved when exoso
作者
高玉婷
李冬
孙祖俊
Gao Yuting;Li Dong;Sun Zujun(Department of Laboratory Medicine,Shanghai Tongji Hospital,School of Medicine,Tongji University,Shanghai200065,China)
出处
《中华检验医学杂志》
CAS
CSCD
北大核心
2024年第8期872-878,共7页
Chinese Journal of Laboratory Medicine
基金
国家自然科学基金(81974314)
2022年同济大学“双带头人”教师党支部书记学术能力提升计划(1508219137)。
